There are progressive MS treatments being studied.
#ECTRIMS2022 – ATA188 Could Be ‘Game Changing’ for Progressive MS
Atara's therapy candidate shown to stabilize or ease disability up to 4 years
In an early clinical trial, Atara Biotherapeutics’ investigational treatment ATA188 stabilized or eased disability in most people with non-active, progressive forms of multiple sclerosis (MS) — with those benefits now having been sustained for up to four years.
#ECTRIMS2022 – Targeting EBV Key in Progressive MS: Experts | ATA188 May Be 'Game Changing' Treatment for Non-active Forms | Multiple Sclerosis News Today
#ECTRIMS2022 – ATA188 Could Be ‘Game Changing’ for Progressive MS
Atara's therapy candidate shown to stabilize or ease disability up to 4 years
In an early clinical trial, Atara Biotherapeutics’ investigational treatment ATA188 stabilized or eased disability in most people with non-active, progressive forms of multiple sclerosis (MS) — with those benefits now having been sustained for up to four years.
#ECTRIMS2022 – Targeting EBV Key in Progressive MS: Experts | ATA188 May Be 'Game Changing' Treatment for Non-active Forms | Multiple Sclerosis News Today
Comment